TRIM72, tripartite motif containing 72, 493829

N. diseases: 34; N. variants: 0
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0026850
Disease: Muscular Dystrophy
Muscular Dystrophy 		0.050 Biomarker disease BEFREE There is great potential for the use of recombinant human MG53 in treating muscular dystrophy and other diseases in which compromised membrane integrity contributes to the disease. 23699904 2013
CUI: C0026850
Disease: Muscular Dystrophy
Muscular Dystrophy 		0.050 GeneticVariation disease BEFREE No pathogenic MG53 mutations were identified in 50 muscular dystrophy patients, suggesting that MG53 is unlikely to be a common cause of muscular dystrophy in Australia. 21412170 2011
CUI: C0026850
Disease: Muscular Dystrophy
Muscular Dystrophy 		0.050 AlteredExpression disease BEFREE Here, we show that systemic delivery and muscle-specific overexpression of human MG53 gene by recombinant adeno-associated virus (AAV) vectors enhanced membrane repair, ameliorated pathology, and improved muscle and heart functions in δ-sarcoglycan (δ-SG)-deficient TO-2 hamsters, an animal model of MD and congestive heart failure. 22314291 2012
CUI: C0026850
Disease: Muscular Dystrophy
Muscular Dystrophy 		0.050 Biomarker disease BEFREE Our recent studies show that MG53 is essential for muscle membrane repair, and defects in MG53 function are linked to muscular dystrophy and cardiac dysfunction. 21343302 2011
CUI: C0026850
Disease: Muscular Dystrophy
Muscular Dystrophy 		0.050 GeneticVariation disease BEFREE Membrane repair defects in muscular dystrophy are linked to altered interaction between MG53, caveolin-3, and dysferlin. 19380584 2009
CUI: C0011860
Disease: Diabetes Mellitus, Non-Insulin-Dependent
Diabetes Mellitus, Non-Insulin-Dependent 		0.020 Biomarker disease BEFREE Furthermore, the potential involvement of circulating MG53 in the pathogenesis of T2DM was assessed by neutralizing blood MG53 with monoclonal antibodies in diabetic db/db mice. 30586741 2019
CUI: C0011860
Disease: Diabetes Mellitus, Non-Insulin-Dependent
Diabetes Mellitus, Non-Insulin-Dependent 		0.020 Biomarker disease BEFREE These results indicated that MSC infusion has therapeutic effects in rats and that MG53 in skeletal muscle may be a promising novel therapeutic target protein for MSC‑mediated amelioration of insulin resistance in T2D. 29693163 2018
CUI: C0018801
Disease: Heart failure
Heart failure 		0.020 Biomarker disease BEFREE Enhancing muscle membrane repair by gene delivery of MG53 ameliorates muscular dystrophy and heart failure in δ-Sarcoglycan-deficient hamsters. 22314291 2012
CUI: C0018801
Disease: Heart failure
Heart failure 		0.020 Biomarker disease BEFREE Herein, we will review the link between structural and molecular remodelling of the sarcolemma associated with the progression of HF, specifically considering the evidence for: (i) Whether intrinsic, evolutionary conserved, plasma membrane injury-repair mechanisms are in operation in the heart, and (ii) if deficits in key 'wound-healing' proteins (annexins, dysferlin, EHD2 and MG53) may play a yet to be fully appreciated role in triggering sarcolemma microdomain remodelling and/or necrosis. 31520263 2019
CUI: C0018802
Disease: Congestive heart failure
Congestive heart failure 		0.020 AlteredExpression disease BEFREE Here, we show that systemic delivery and muscle-specific overexpression of human MG53 gene by recombinant adeno-associated virus (AAV) vectors enhanced membrane repair, ameliorated pathology, and improved muscle and heart functions in δ-sarcoglycan (δ-SG)-deficient TO-2 hamsters, an animal model of MD and congestive heart failure. 22314291 2012
CUI: C0018802
Disease: Congestive heart failure
Congestive heart failure 		0.020 Biomarker disease BEFREE Herein, we will review the link between structural and molecular remodelling of the sarcolemma associated with the progression of HF, specifically considering the evidence for: (i) Whether intrinsic, evolutionary conserved, plasma membrane injury-repair mechanisms are in operation in the heart, and (ii) if deficits in key 'wound-healing' proteins (annexins, dysferlin, EHD2 and MG53) may play a yet to be fully appreciated role in triggering sarcolemma microdomain remodelling and/or necrosis. 31520263 2019
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X 		0.020 Biomarker disease BEFREE TRIM72 is involved in insulin resistance and metabolic syndrome, which are risk factors of colon cancer. 29806630 2018
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X 		0.020 Biomarker disease BEFREE Using perfused rodent hearts or skeletal muscle, we investigated whether high glucose, high insulin, or their combination (conditions mimicking metabolic syndrome or T2DM) alters MG53 protein concentration in the perfusate. 30586741 2019
CUI: C0699790
Disease: Colon Carcinoma
Colon Carcinoma 		0.020 AlteredExpression disease BEFREE Importantly, the lower serum TRIM72 levels were associated with advanced clinical stage, lymph node, and distant metastases in colon cancer patients. 29806630 2018
CUI: C0699790
Disease: Colon Carcinoma
Colon Carcinoma 		0.020 AlteredExpression disease BEFREE The aim of this study is to determine the potential predictive value of TRIM72 immunohistochemical expression in stage II colon carcinoma. 30852740 2019
CUI: C0004238
Disease: Atrial Fibrillation
Atrial Fibrillation 		0.010 AlteredExpression disease BEFREE Expression of MG53 increased with the extent of atrial fibrosis, which could induce AF. 29233682 2018
CUI: C0007102
Disease: Malignant tumor of colon
Malignant tumor of colon 		0.010 AlteredExpression disease BEFREE Importantly, the lower serum TRIM72 levels were associated with advanced clinical stage, lymph node, and distant metastases in colon cancer patients. 29806630 2018
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma 		0.010 Biomarker disease BEFREE TRIM72 Immunohistochemical Expression Can Predict Relapse in Colorectal Carcinoma. 30852740 2019
CUI: C0013264
Disease: Muscular Dystrophy, Duchenne
Muscular Dystrophy, Duchenne 		0.010 Biomarker disease BEFREE MG53 has been implicated in cardiac ischaemia-reperfusion injury, and serum MG53 provides a biomarker of skeletal muscle injury in the mdx mouse model of Duchenne muscular dystrophy. 26790476 2016
CUI: C0020459
Disease: Hyperinsulinism
Hyperinsulinism 		0.010 Biomarker disease BEFREE First, high glucose or high insulin induces MG53 secretion from isolated rodent hearts and skeletal muscle. 30586741 2019
CUI: C0085612
Disease: Ventricular arrhythmia
Ventricular arrhythmia 		0.010 Biomarker disease BEFREE MG53 knockout enhances I<sub>to,f</sub> remodeling and action potential duration prolongation and increases susceptibility to ventricular arrhythmia in mouse cardiac hypertrophy. 30760025 2019
CUI: C0153349
Disease: Malignant neoplasm of tongue
Malignant neoplasm of tongue 		0.010 Biomarker disease BEFREE Here, the role of MG53 in the tumorigenesis of tongue cancer is analyzed in vitro and in vivo. 30690890 2019
CUI: C0558353
Disease: Tongue Carcinoma
Tongue Carcinoma 		0.010 Biomarker disease BEFREE The findings demonstrate that MG53 affects the biological behavior of human tongue cancer SCC9 and SCC25 cells. 30690890 2019
CUI: C0919747
Disease: Cytokine storm
Cytokine storm 		0.010 Biomarker disease BEFREE Genetic ablation of TRIM72 led to improved pathogen clearance, reduced cytokine storm, and improved survival in murine models of severe pneumonia, specificity of which was confirmed by adoptive transfer of wild-type or TRIM72<sup>KO</sup> AMs to AM-depleted TRIM72<sup>KO</sup> mice. 29268030 2018
CUI: C1260873
Disease: Aortic valve disorder
Aortic valve disorder 		0.010 Biomarker disease BEFREE Methods and Results We found that MG 53 is expressed in pig and human patient aortic valves and observed aortic valve disease in aged Mg53-/- mice. 30741589 2019